Physician profile
Yusra Arooj
NPI 1255029682
$259.67
in general payments reported to CMS, 2019-2025
13 companies · $91.14 in 2025
The $91.14 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.00 · 2024: $129 · 2025: $91.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.84 | 2024 | |
| Calliditas Therapeutics US INC. | $24.54 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $22.57 | 2023 | Tezspire |
| Lilly USA, LLC | $22.35 | 2024 | Mounjaro |
| Viiv Healthcare Company | $20.23 | 2024 | Apretude |
| Heartflow, INC. | $20.16 | 2025 | |
| Amgen INC. | $17.43 | 2023 | Repatha |
| Abbvie INC. | $16.84 | 2025 | |
| Merck Sharp & Dohme LLC | $15.82 | 2025 | Verquvo |
| Cumberland Pharmaceuticals, INC. | $14.86 | 2024 | Caldolor |
| Novartis Pharmaceuticals Corporation | $13.94 | 2024 | |
| Glaxosmithkline, LLC. | $13.78 | 2025 | Arexvy, Shingrix |
| Csl Behring | $13.31 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusra Arooj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.